Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APLS Apellis Pharmaceuticals Inc.

休市中 05-03 16:00:00 EDT

47.46

-0.03

-0.06%

盘后47.41

-0.05-0.11%

19:57 EDT

最高48.76	最低47.22	成交量110.67万
今开48.46	昨收47.49	日振幅3.24%
总市值57.57亿	流通市值38.80亿	总股本1.21亿
成交额5,279万	换手率1.35%	流通股本8,175万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"APLS","market":"US","secType":"STK","nameCN":"Apellis Pharmaceuticals Inc.","latestPrice":47.46,"timestamp":1714766400000,"preClose":47.49,"halted":0,"volume":1106743,"hourTrading":{"tag":"盘后","latestPrice":47.41,"preClose":47.46,"latestTime":"19:57 EDT","volume":11921,"amount":565888.8232,"timestamp":1714780649892},"delay":0,"floatShares":81752460,"shares":121293768,"eps":-4.454304,"marketStatus":"休市中","marketStatusCode":7,"change":-0.03,"latestTime":"05-03 16:00:00 EDT","open":48.46,"high":48.76,"low":47.22,"amount":52786151.65472,"amplitude":0.032428,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.454304,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1714982400000},"adr":0,"listingDate":1510203600000,"adjPreClose":47.49,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":48.28,"preClose":47.49,"latestTime":"09:14 EDT","volume":143,"amount":6939.1550799999995,"timestamp":1714742076865},"postHourTrading":{"tag":"盘后","latestPrice":47.41,"preClose":47.46,"latestTime":"19:57 EDT","volume":11921,"amount":565888.8232,"timestamp":1714780649892},"volumeRatio":0.4379271394416257},"requestUrl":"/m/hq/s/APLS/wiki","defaultTab":"wiki","newsList":[{"id":"2432662901","title":"Apellis Pharmaceuticals Inc    预计每股亏损 52 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2432662901","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2432662901?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:55","pubTimestamp":1714748139,"startTime":"0","endTime":"0","summary":"   * Apellis Pharmaceuticals Inc    将于5月7日公布截至2024年3月31日的财报，预计该公司的季度收入将有所增长。* LSEG 分析师对 Apellis Pharmaceuticals Inc 的平均预期是每股亏损 52 美分。* 华尔街对 Apellis Pharmaceuticals Inc 的 12 个月目标价中位数为 84.00 美元，高于其上次收盘价 47.49 美元。5月3日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2431267943","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.14%报45.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2431267943","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431267943?lang=zh_cn&edition=full","pubTime":"2024-04-30 21:45","pubTimestamp":1714484714,"startTime":"0","endTime":"0","summary":"北京时间2024年04月30日21时45分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.01%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043021451579258605&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430072302","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大涨5.03%报50.34美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430072302","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430072302?lang=zh_cn&edition=full","pubTime":"2024-04-26 23:54","pubTimestamp":1714146846,"startTime":"0","endTime":"0","summary":"北京时间2024年04月26日23时54分，Apellis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.03%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240426235406861e9966&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430282069","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.05%报47.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430282069","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430282069?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:35","pubTimestamp":1714055747,"startTime":"0","endTime":"0","summary":"北京时间2024年04月25日22时35分，Apellis Pharmaceuticals, Inc.股票出现异动，股价快速下挫5.05%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.84%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404252235487a55b949&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428378134","title":"Apellis Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.00%报49.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2428378134","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428378134?lang=zh_cn&edition=full","pubTime":"2024-04-18 03:11","pubTimestamp":1713381116,"startTime":"0","endTime":"0","summary":"北京时间2024年04月18日03时11分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.00%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：Wedbush：维持Apellis Pharmaceuticals评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180311567a538294&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428326302","title":"Wedbush：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428326302","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428326302?lang=zh_cn&edition=full","pubTime":"2024-04-18 00:35","pubTimestamp":1713371710,"startTime":"0","endTime":"0","summary":"Wedbush：维持Apellis Pharmaceuticals(APLS.US)评级，由中性调整至中性评级, 目标价由67.00美元调整至57.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180035148b30d71c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404180035148b30d71c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426738916","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426738916","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426738916?lang=zh_cn&edition=full","pubTime":"2024-04-12 21:52","pubTimestamp":1712929938,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日21时52分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅下跌5.17%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.26%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。该信息摘要如下：Needham：重申Apellis Pharmaceuticals评级，由买入调整至买入评级, 目标价85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041221521879203ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041221521879203ae6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426161509","title":"Needham：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价85.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2426161509","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426161509?lang=zh_cn&edition=full","pubTime":"2024-04-09 18:45","pubTimestamp":1712659528,"startTime":"0","endTime":"0","summary":"Needham：重申Apellis Pharmaceuticals(APLS.US)评级，由买入调整至买入评级, 目标价85.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845298b03185e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404091845298b03185e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2424007045","title":"Apellis Pharmaceuticals, Inc.盘中异动 快速下挫5.33%报56.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2424007045","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2424007045?lang=zh_cn&edition=full","pubTime":"2024-04-02 21:50","pubTimestamp":1712065803,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日21时50分，Apellis Pharmaceuticals, Inc.股票出现波动，股价快速下跌5.33%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。消息层面，截至21时50分，《Form 144 | Apellis Pharmaceuticals高管拟出售4,000股股份，价值约23.46万美元》资讯为影响Apellis Pharmaceuticals, Inc.的重要信息。该信息摘要如下：根据美国证券交易委员会美东时间4月1日披露的文件，$Apellis Pharmaceuticals $高管Sullivan Timothy Eugene拟于4月1日出售4,000股普通股股份，总市值约23.46万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221500387e7da23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040221500387e7da23&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422619617","title":"Apellis Pharmaceuticals, Inc.盘中异动 早盘急速拉升5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422619617","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422619617?lang=zh_cn&edition=full","pubTime":"2024-03-26 21:58","pubTimestamp":1711461533,"startTime":"0","endTime":"0","summary":"北京时间2024年03月26日21时58分，Apellis Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.09%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240326215853861e1429&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240326215853861e1429&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420309740","title":"Apellis Pharmaceuticals, Inc.盘中异动 股价大跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420309740","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420309740?lang=zh_cn&edition=full","pubTime":"2024-03-20 21:40","pubTimestamp":1710942001,"startTime":"0","endTime":"0","summary":"北京时间2024年03月20日21时40分，Apellis Pharmaceuticals, Inc.股票出现异动，股价急速跳水5.02%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.77%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家处于商业化阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗具有高度未满足需求的疾病，在补体级联反应中的中心蛋白C3水平上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320214001791bbeb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240320214001791bbeb6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417200459","title":"美国研究综述-树皮、Fleetcor Technologies、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2417200459","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417200459?lang=zh_cn&edition=full","pubTime":"2024-03-05 14:57","pubTimestamp":1709621845,"startTime":"0","endTime":"0","summary":"    路透社3月5日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Bark、Fleetcor Technologies 和特斯拉。要闻             * Bark Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入\"；将交易价从1.54美元上调至1.9美元。* Fleetcor Technologies Inc   ：贝尔德将其评级上调至 \"跑赢大盘\"。* 特斯拉  ：加拿大皇家银行将目标价从297美元上调至298美元 以下是路透社周二报道的美国公司研究报告摘要。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417176870","title":"美国研究综述-CommScope Holding Company、Dutch Bros、Hess","url":"https://stock-news.laohu8.com/highlight/detail?id=2417176870","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417176870?lang=zh_cn&edition=full","pubTime":"2024-03-05 03:21","pubTimestamp":1709580103,"startTime":"0","endTime":"0","summary":"    路透社3月4日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价，其中包括 CommScope Holding Company、Dutch Bros 和 Hess。要点 * CommScope Holding Company   ：摩根大通将其股票评级从中性下调至减持  * 荷兰兄弟  ：Piper Sandler 将其评级从中性上调至增持  * Hess Corp   ：Susquehanna 将目标价从 152 美元上调至 156 美元  * Pioneer Natural Resources Co   ：苏斯克汉纳将目标价从237美元上调至246美元  * United Therapeutics Corp   ：摩根大通将目标价从294美元下调至280美元  以下是路透社周一报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2416957623","title":"Apellis Pharmaceuticals, Inc.盘中异动 急速上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416957623","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416957623?lang=zh_cn&edition=full","pubTime":"2024-03-02 00:19","pubTimestamp":1709309967,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日00时19分，Apellis Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.07%。截至发稿，该股报65.11美元/股，成交量63.3654万股，换手率0.53%，振幅5.61%。Apellis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.44%。其相关个股中，Biovie Inc.、Adial Pharmaceuticals, Inc、Cardiff Oncology, Inc.涨幅较大，Adial Pharmaceuticals, Inc、Enveric Biosciences, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为3700.26%、401.75%、335.02%，振幅较大的相关个股有Biovie Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Jaguar Health, Inc.，振幅分别为96.77%、81.48%、81.19%。Apellis Pharmaceuticals, Inc.公司简介：Apellis Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020019287a489b78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403020019287a489b78&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2415030376","title":"Apellis Pharmaceuticals Inc盘中异动 早盘股价大跌5.16%报65.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415030376","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2415030376?lang=zh_cn&edition=full","pubTime":"2024-02-28 23:23","pubTimestamp":1709133836,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日23时23分，Apellis Pharmaceuticals Inc股票出现波动，股价快速下跌5.16%。截至发稿，该股报65.77美元/股，成交量25.3123万股，换手率0.21%，振幅6.39%。Apellis Pharmaceuticals Inc股票所在的生物技术行业中，整体跌幅为0.25%。其相关个股中，Vivani Medical Inc、Adial Pharmaceuticals Inc、Dermata Therapeutics Inc C/Wts 13/08/2026 涨幅较大，Adial Pharmaceuticals Inc、Vivani Medical Inc、Zyversa Therapeutics Inc较为活跃，换手率分别为1762.90%、160.03%、73.32%，振幅较大的相关个股有Vivani Medical Inc、Adial Pharmaceuticals Inc、Psyence Biomedical Ltd C/Wts 25/01/2029，振幅分别为339.60%、171.75%、86.89%。Apellis Pharmaceuticals Inc公司简介：Apellis Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240228232356861d9ab7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240228232356861d9ab7&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414347453","title":"美国研究综述-星座能源、埃塞克斯财产信托、斯特林基础设施","url":"https://stock-news.laohu8.com/highlight/detail?id=2414347453","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2414347453?lang=zh_cn&edition=full","pubTime":"2024-02-28 20:07","pubTimestamp":1709122035,"startTime":"0","endTime":"0","summary":"    路透社2月28日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括星座能源公司、埃塞克斯房地产信托公司和斯特林基础设施公司。要闻 * Apartment Income REIT Corp   ：瑞穗将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2414803595","title":"Apellis Pharmaceuticals Inc盘中异动 快速下跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2414803595","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2414803595?lang=zh_cn&edition=full","pubTime":"2024-02-27 22:30","pubTimestamp":1709044259,"startTime":"0","endTime":"0","summary":"北京时间2024年02月27日22时30分，Apellis Pharmaceuticals Inc股票出现异动，股价急速下挫5.06%。截至发稿，该股报68.10美元/股，成交量3.8209万股，换手率0.03%，振幅0.59%。Apellis Pharmaceuticals Inc股票所在的生物技术行业中，整体涨幅为0.62%。其相关个股中，Janux Therapeutics Inc、Viking Therapeutics Inc、Revolution Medicines Inc C/Wts 17/12/2026 涨幅较大，Scisparc Ltd、Zyversa Therapeutics Inc、Galera Therapeutics Inc较为活跃，换手率分别为301.11%、82.14%、29.46%，振幅较大的相关个股有Viking Therapeutics Inc、Janux Therapeutics Inc、Fate Therapeutics，振幅分别为13.46%、12.85%、11.08%。Apellis Pharmaceuticals Inc公司简介：Apellis Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240227223059861d8d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240227223059861d8d8c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413557793","title":"Apellis Pharmaceuticals Inc    预计每股亏损 69 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2413557793","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413557793?lang=zh_cn&edition=full","pubTime":"2024-02-23 23:30","pubTimestamp":1708702205,"startTime":"0","endTime":"0","summary":"   * Apellis Pharmaceuticals Inc    将于2月27日公布截至2023年12月31日的季度财报，预计该公司的季度收入将有所增长。   * LSEG 分析师对 Apellis Pharmaceuticals Inc 的平均预期是每股亏损 69 美分。* 华尔街对 Apellis Pharmaceuticals Inc 的 12 个月目标价中位数为 80.00 美元，高于其上次收盘价 67.59 美元。2月23日 - 上一季度业绩。除非另有说明，所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411943656","title":"Apellis Pharmaceuticals Inc    预计每股亏损 69 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2411943656","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2411943656?lang=zh_cn&edition=full","pubTime":"2024-02-16 19:32","pubTimestamp":1708083129,"startTime":"0","endTime":"0","summary":"   * Apellis Pharmaceuticals Inc    预计将在2月19日公布截至2023年12月31日的季度业绩(预计)，季度收入将有所增长。* 根据 16 位分析师基于 LSEG 数据的平均预期，这家总部位于美国马萨诸塞州沃尔瑟姆市的公司的营收预计将从去年同期的 2266 万美元增长 533.6%，达到 1.43593 亿美元。   * LSEG 分析师对 Apellis Pharmaceuticals Inc 的平均预期是每股亏损 69 美分。* 华尔街对 Apellis Pharmaceuticals Inc 的 12 个月目标价中位数为 80.00 美元，高于其上次收盘价 67.58 美元。2月16日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409433344","title":"Apellis Pharmaceuticals Inc盘中异动 早盘股价大涨6.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2409433344","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2409433344?lang=zh_cn&edition=full","pubTime":"2024-02-05 22:32","pubTimestamp":1707143544,"startTime":"0","endTime":"0","summary":"北京时间2024年02月05日22时32分，Apellis Pharmaceuticals Inc股票出现异动，股价急速上涨6.63%。Apellis Pharmaceuticals Inc股票所在的生物技术行业中，整体跌幅为0.20%。其相关个股中，4D Molecular Therapeutics Inc、180 Life Sciences Corp C/Wts 07/11/2025、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Biorestorative Therapies Inc、Revelation Biosciences Inc、Genprex Inc较为活跃，换手率分别为125.35%、40.81%、38.47%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Revelation Biosciences Inc C/Wts 10/01/2027 、Pliant Therapeutics Inc，振幅分别为31.58%、25.64%、14.66%。Apellis Pharmaceuticals Inc公司简介：Apellis Pharmaceuticals Inc是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240205223224877166b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240205223224877166b6&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.apellis.com","stockEarnings":[{"period":"1week","weight":-0.0481},{"period":"1month","weight":-0.1666},{"period":"3month","weight":-0.2414},{"period":"6month","weight":0.0135},{"period":"1year","weight":-0.4375},{"period":"ytd","weight":-0.2072}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.0343},{"period":"6month","weight":0.1762},{"period":"1year","weight":0.262},{"period":"ytd","weight":0.0757}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Apellis Pharmaceuticals, Inc.于2009年9月25日根据德拉华州法律成立。该公司是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，通过在补体级联中的中心蛋白C3水平上抑制补体系统（作为免疫系统的一个组成部分）来治疗具有高度未满足需求的疾病。2023年2月，美国食品药品监督管理局（FDA）批准了SYFOVRE，这是首个获批治疗继发于年龄相关性黄斑变性（GA）的地理萎缩的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.018331},{"month":2,"riseRate":0.714286,"avgChangeRate":0.056236},{"month":3,"riseRate":0.571429,"avgChangeRate":0.044074},{"month":4,"riseRate":0.714286,"avgChangeRate":0.062825},{"month":5,"riseRate":0.571429,"avgChangeRate":0.001384},{"month":6,"riseRate":0.833333,"avgChangeRate":0.097286},{"month":7,"riseRate":0.5,"avgChangeRate":-0.121496},{"month":8,"riseRate":1,"avgChangeRate":0.171387},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.124118},{"month":10,"riseRate":0.5,"avgChangeRate":0.026944},{"month":11,"riseRate":0.666667,"avgChangeRate":0.131706},{"month":12,"riseRate":0.857143,"avgChangeRate":0.150428}],"exchange":"NASDAQ","name":"Apellis Pharmaceuticals Inc.","nameEN":"Apellis Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Apellis Pharmaceuticals Inc.,APLS,Apellis Pharmaceuticals Inc.股票,Apellis Pharmaceuticals Inc.股票老虎,Apellis Pharmaceuticals Inc.股票老虎国际,Apellis Pharmaceuticals Inc.行情,Apellis Pharmaceuticals Inc.股票行情,Apellis Pharmaceuticals Inc.股价,Apellis Pharmaceuticals Inc.股市,Apellis Pharmaceuticals Inc.股票价格,Apellis Pharmaceuticals Inc.股票交易,Apellis Pharmaceuticals Inc.股票购买,Apellis Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Apellis Pharmaceuticals Inc.(APLS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Apellis Pharmaceuticals Inc.(APLS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况